Innate Pharma To Present Interim Results Of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria At The EORTC Meeting 2023
Portfolio Pulse from Benzinga Newsdesk
Innate Pharma will present interim results of its Phase 2 TELLOMAK study with Lacutamab, using updated Olsen 2022 criteria, at the EORTC Meeting in 2023.
September 22, 2023 | 6:45 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Innate Pharma's presentation of interim results of its Phase 2 TELLOMAK study could potentially impact its stock price.
The presentation of interim results of a Phase 2 study is a significant event for a biotech company like Innate Pharma. However, without knowing the results, it's hard to predict the direction of the impact. Positive results could boost the stock, while negative results could have the opposite effect.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100